- Sickle Cell Disease Insights
- Posts
- Weekly Spotlight - 09.01.25
Weekly Spotlight - 09.01.25
Unveiling the Genetic Key to Managing Sickle Cell Anemia Complications
Liam Ball
January 09, 2025 • Estimated Reading Time: 3 minutes
Community |
Your journey can be a beacon of hope and a source of strength for others in our community. Together, we can build a stronger, more supportive community. Your story matters, and it deserves to be heard. Fill in this form to be featured. |
Latest News
The study explores the role of the endocannabinoid system (ECS) in managing sickle cell anaemia complications, specifically priapism. It found that certain ECS genetic variations might reduce priapism risk. This suggests a potential new treatment approach that targets these genetic pathways to offer hope for sufferers.
Orna Therapeutics has announced a £4.3 billion collaboration with Vertex Pharmaceuticals, focusing on advanced treatments for sickle cell and thalassemia. This marks a significant step verifying Orna’s lipid nanoparticle technology, acquired last year. The partnership promises to benefit patients through innovative gene therapies.
Clinicians are seeking immune cell biomarkers and anti-inflammatory therapies for sickle cell disease (SCD). Emerging biomarkers may lead to better drugs and therapies. Current treatments like hydroxyurea have limited success, facing complexity and high costs. Trials in affected regions like Africa are vital for progress and understanding.
Source: DocWireNews
Health Spotlight’s Sickle Cell Disease is a Contentive publication in the Healthcare division